Based on these results, we speculate that PI3K/AKT signaling inhibitors may be effective at inhibiting tumor development in ESCC patients with high IKBIP expression but may be ineffective at preventing tumor development in ESCC patients with low IKBIP expression. The gene discussed is AKT1; the disease is esophageal squamous cell carcinoma.